Fate Therapeutics (FATE) Profit After Tax (2012 - 2026)

Fate Therapeutics has reported Profit After Tax for 15 years, with the latest figure at -$31.2 million in Q1 2026.

• For the quarter ending Q1 2026, Profit After Tax rose 17.03% year-over-year to -$31.2 million; the trailing twelve-month figure through Mar 2026 stood at -$129.9 million (up 26.14% YoY), and the FY2025 full-year result was -$136.3 million, up 26.82% from the prior year.
• Profit After Tax for Q1 2026 stood at -$31.2 million, up from -$32.4 million in the prior quarter.
• The five-year high for Profit After Tax was -$18.9 million in Q1 2023, with the low at -$83.6 million in Q3 2022.
• Historically, Profit After Tax has averaged -$46.8 million across 5 years, with a median of -$45.2 million in 2023.
• Annual changes were most pronounced in 2023 — Profit After Tax jumped 71.26% — and 2024, when it tumbled 154.25%.
• Fate Therapeutics' Profit After Tax stood at -$56.4 million in 2022, then climbed by 21.72% to -$44.1 million in 2023, then slipped by 18.2% to -$52.2 million in 2024, then surged by 37.92% to -$32.4 million in 2025, then gained by 3.59% to -$31.2 million in 2026.
• The last three Profit After Tax figures came in at -$31.2 million (Q1 2026), -$32.4 million (Q4 2025), and -$32.2 million (Q3 2025), per Business Quant data.